Pathos AI Partners with Bristol Myers and Tempus AI for Neurological Drug Development
Pathos AI has partnered with Bristol Myers Squibb and Tempus AI to develop AI tools targeting Alzheimer's and other neurological disorders. The collaboration includes a $237 million Series E funding led by Bristol Myers, valuing Pathos at $3 billion. Tempus will create a large neurological dataset, licensed by Pathos for $55 million over five years. Pathos will use its AI platform to analyze data and aid clinical trial design. Bristol Myers gains strategic and exclusive neuroscience access for three years.
ET Tech··New York




